ANTIPSYCHOTICS PRIOR AUTHORIZATION FORM

(form effective 1/6/2025)



AmeriHealth Caritas Pennsylvania PERFORMR

Next Generation Pharmacy Benefits

Fax to PerformRx[™] at **1-855-851-4058**, or to speak to a representative call **1-888-674-8720**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
□ New request □ Renewal request	Total pages: Office contact/ph	one: LTC f	acility contact/phone:
PATIENT INFORMATION			
Patient name:		Patient ID#:	DOB:
Street address:	At	ot #: City/state/zip:	
PRESCRIBER INFORMATION			
Prescriber name:			
Specialty:		NPI:	State license #:
Street address:	Si	uite #: City/state/zip:	
Phone:	L	Fax:	
MEDICATION REQUESTED		·	
Preferred Agents			
Non-Injectable			
□ Aripiprazole Tablet	🗆 Haloperidol Tablet	🗆 Olanzapine Tablet	□ Risperidone Solution
Clozapine Tablet	Haloperidol Lactate Oral	Paliperidone ER Tablet	🗆 Risperidone Tablet
Equetro (carbamazepine) Capsule	Concentrate Solution	Perphenazine Tablet	Trifluoperazine Tablet
Fluphenazine Oral Concentrate Solution Fluphenazine Tablet	Loxapine Capsule	Quetiapine Tablet	Ziprasidone Capsule
Fluphenazine Tablet	Lurasidone Tablet	🗆 Quetiapine ER Tablet	
Injectable Abilify Asimtufii (aripiprazole)	Fluphenazine Decanoate Vial	Haloperidol Lactate Vial	Perseris ER (risperidone)
□ Abilify Maintena (aripiprazole)	□ Haloperidol Decanoate Ampule	Invega Hafyera (paliperidone)	□ Risperdal Consta (risperidone)
□ Aristada ER (aripiprazole lauroxil)	□ Haloperidol Decanoate Vial	Invega Sustenna (paliperidone)	Rykindo (risperidone) Vial
Aristada Initio (aripiprazole lauroxil)	Haloperidol Lactate Syringe	🗆 Invega Trinza (paliperidone)	Uzedy ER (risperidone)
Strength:	Dosage form:	Directions:	
Diagnosis:			
Non-Preferred Agents			
Non-Injectable			
□ Abilify (aripiprazole) Tablet	🗆 Clozaril (clozapine) Tablet	🗆 Olanzapine ODT	Seroquel XR (quetiapine) Tablet
□ Abilify Mycite (aripiprazole tablet +	🗆 Fanapt (iloperidone) Tablet	Olanzapine-Fluoxetine Capsule	Symbyax (olanzapine-fluoxetine) Capsule
sensor)	Fluphenazine Elixir	🗆 Perphenazine-Amitriptyline Tablet	Thioridazine Tablet
□ Adasuve (loxapine) Inhalation Powder	🗆 Geodon (ziprasidone) Capsule	Pimozide Tablet	Thiothixene Capsule
	□ Invega ER (paliperidone) Tablet	Rexulti (brexpiprazole) Tablet	□ Versacloz (clozapine) Suspension
Aripiprazole Solution Accessing SL Tablet	Latuda (lurasidone) Tablet Lybelyi (eleganciae (aemidember) Tablet	Risperdal (risperidone) Solution Disperdal (risperidence) Tablet	□ Vraylar (cariprazine) Capsule
 Asenapine SL Tablet Caplyta (lumateperone) Capsule 	 Lybalvi (olanzapine/samidorphan) Tablet Molindone Tablet 	 Risperdal (risperidone) Tablet Risperidone ODT 	Zyprexa (olanzapine) Tablet Zyprexa (olanzapine) Zydis
Capsule Capsu	Nuplazid (pimavanserin) Capsule	\Box Saphris SL (asenapine) Tablet	□ Zyprexa (olalizapine) zyuis
\Box Chlorpromazine Tablet	Nuplazid (pimavanserin) Sapedie	□ Secuado (asenapine) Patch	
□ Clozapine ODT		□ Seroquel (quetiapine) Tablet	
Injectable			
Chlorpromazine Ampule	🗆 Geodon (ziprasidone) Vial	Risperidone ER Vial	🗆 Zyprexa Relprevv (olanzapine)
Chlorpromazine Vial	Haldol Decanoate (haloperidol) Ampule	Ziprasidone Vial	Zyprexa (olanzapine) Vial
Fluphenazine HCI Vial	🗆 Olanzapine Vial	- I	
Strength:	Dosage form:	Directions:	
Diagnosis:			
PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication):			
Deliver to: Patient's Home Physician's Office Patient's Preferred Pharmacy Name:			
Pharmacy Phone #:		Pharmacy Fax #:	
□ I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.			
REQUEST FOR A NON-PREFERRED AGENT			
1. Has the patient taken the requested non-preferred antipsychotic in the past 90 days? □ Yes – Submit documentation. □ No			
A las the patient taken the requested non-preferred anapsychotic in the past 90 days: □ res = 3ubinit documentation. □ No			
3. Does the patient have a contraindication or intolerance to the preferred medications? 🗆 Yes – Submit documentation of contraindication/intolerance. 🗆 No			



Date:

REQUEST FOR A PATIENT LESS THAN 18 YEARS OF AGE

4. For renewal requests, has the patient had improvement in target symptoms with use of this medication?

- 5. Is this request for a dose increase of a previously approved medication or request over the plan limits? 🗆 Yes Submit recent chart documentation and/or treatment guidelines supporting the requested dose. 🗆 No
- 6. For renewal requests, is there a plan for taper/discontinuation or rationale for continued use of requested drug ? 🗆 Yes Submit supporting documentation. 🗆 No
- 7. Is the requested agent prescribed by, or in consultation with, one of the following physician specialists? 🗆 Yes 👘 No Submit documentation of consultation, if applicable.
- 🗆 child development pediatrician 🗆 child & adolescent psychiatrist 🗆 general psychiatrist (only if patient is ≥ 14 years of age) 🗆 pediatric neurologist
- 8. Does the patient have severe symptoms related to a psychotic or neuro-developmental disorder? 🗆 Yes Submit medical record documentation. 👘 No
- 9. Has chart documented evidence of comprehensive evaluation and plan of care that includes non-drug therapies? 🗆 Yes Submit medical record documentation. 🔅 No
- 10. Has the patient had the following baseline and/or follow-up monitoring? Check all that apply.
 BMI and/or weight (for follow-up monitoring this must be done quarterly)
 fasting blood glucose or hemoglobin a1c
 fasting lipid panel
 presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS)
 Submit documentation of all monitoring/test results and dates.

REQUEST FOR THERAPEUTIC DUPLICATION OF AN ATYPICAL OR TYPICAL ANTIPSYCHOTIC

11. Does the patient have a medical reason for concomitant use of the requested medications? 🗆 Yes – Submit documentation of treatment guidelines supporting concomitant use. 🗅 No

12. Is this request for a drug that is being titrated to, or tapered from, a drug in the same class?
Yes No

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:

<u>Confidentiality Notice:</u> The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.